SCHEMBL5774011

SCHEMBL5774011

OCc1nc2cc(F)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
IDO1 P14902 1/20 0.49
NPSR1 Q6W5P4 1/20 0.46
F10 P00742 2/20 0.44
RHEB Q15382 1/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.38
PDPK1 O15530 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
APEX1 P27695 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DAO P14920 1/20 0.38
POLB P06746 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31345724 0.86 IDO1 (0.66) TDP1IDO1NPSR1F10ALPL
SCHEMBL6640558 0.86 IDO1 (0.66) TDP1IDO1NPSR1F10ALPL
SCHEMBL8417202 0.82 DDAH1 (0.58) TDP1IDO1F10ALDH1A1KDM4E
SCHEMBL20867740 0.82 IDO1 (0.57) IDO1F10ALPLALPIALPG
SCHEMBL1083641 0.82 IDO1 (0.49) TDP1IDO1F10ALPLALPI
SCHEMBL16808069 0.81 L3MBTL1 (0.40) TDP1IDO1NPSR1F10ALPL
Hydrochloric Acid SCHEMBL23497518 0.81 IDO1 (0.55) IDO1F10ALPLALPIALPG
Hydrochloric Acid SCHEMBL22228556 0.81 IDO1 (0.55) IDO1F10ALPLALPIALPG
SCHEMBL9513404 0.80 TSHR (0.47) TDP1IDO1F10ALDH1A1KDM4E
SCHEMBL13351516 0.79 IDO1 (0.54) IDO1ALDH1A1KDM4EPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9323153-B2 Actinic ray-sensitive or radiation-sensitive resin composition, and, actinic ray-sensitive or radiation-sensitive film and pattern forming method, each using the same FUJIFILM CORPORATION (JP) 2016-04-26 US disclosed
US-9323153-B2 Actinic ray-sensitive or radiation-sensitive resin composition, and, actinic ray-sensitive or radiation-sensitive film and pattern forming method, each using the same FUJIFILM CORPORATION (JP) 2016-04-26 US disclosed
US-20150168415-A1 COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS ACADEMIA SINICA (TW) 2015-06-18 US disclosed
US-20150004533-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM AND PATTERN FORMING METHOD, EACH USING THE SAME FUJIFILM CORPORATION (JP) 2015-01-01 US disclosed
US-20150004533-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM AND PATTERN FORMING METHOD, EACH USING THE SAME FUJIFILM CORPORATION (JP) 2015-01-01 US disclosed
EP-1671972-A1 Octahydropyrrolo[3,4-c]pyrrole derivatives Pfizer Limited (GB) 2006-06-21 EP disclosed
US-20060111416-A1 Octahydropyrrolo[3,4-C]pyrrole derivatives PFIZER INC. 2006-05-25 US disclosed
EP-1311268-A4 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2004-06-30 EP disclosed
CN-1436079-A Imidazopyridine and imidazopyrimidine antiviral agent BRISTOL MYERS SQUIBB CO (US) 2003-08-13 CN disclosed
EP-1311268-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-21 EP disclosed
US-6489338-B2 TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION. BRISTOL-MYERS SQUIBB COMPANY 2002-12-03 US disclosed
US-20020016309-A1 Imidazopyridine and imidazopyrimidine antiviral agents BRISTOL-MEYERS SQUIBB COMPANY 2002-02-07 US disclosed
WO-2001095910-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111416-A1 Octahydropyrrolo[3,4-C]pyrrole derivatives DPYD, PAH, DHPS TDP1 1015/4885IDO1 806/4885NPSR1 331/4885
US-20150168415-A1 COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS MPI, GPI, FUT6 TDP1 4340/4885IDO1 2365/4885NPSR1 3475/4885
US-20020016309-A1 Imidazopyridine and imidazopyrimidine antiviral agents MAVS, ZC3HAV1, EIF2AK2 TDP1 1773/4885IDO1 235/4885NPSR1 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.